Syndax Pharmaceuticals, Inc. SNDX
18.20
0.23
1.28%
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow SNDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (255.93%) | (189.53%) | (161.82%) | (129.32%) |
+8 more TTM periods Free account |
|
| (33.97%) | (43.70%) | (45.50%) | (63.74%) | ||
ROIC |
(247.93%) | (573.79%) | 0.00% | (3,712.99%) | |
Return on Tangible Assets |
(38.36%) | (63.15%) | (69.93%) | (74.94%) | |
Average Days of Receivables |
101.57 | 98.98 | 144.31 | 134.61 | |
Free Cash Flow per Share |
(2.48) | (3.15) | (3.73) | (5.49) | |
Free Cash Flow |
(220.87) | (278.16) | (322.94) | (475.42) | |
Capital Expenditures |
(0.23) | — | 0.04 | (164.54) | |
Piotroski F-Score |
4.00 | 2.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(19.06%) | (37.25%) | (39.28%) | (34.03%) | |
Accounts Receivable Turnover |
4.78 | 5.55 | 4.34 | 5.00 | |
Accounts Payable Turnover |
0.96 | 0.83 | 0.49 | 0.46 | |
Inventory Turnover |
0.42 | 0.44 | 0.42 | 0.00 | |
Average Days of Payables |
167.09 | 453.97 | 868.25 | 1,182.68 | |
Days of Inventory on Hand |
1,136.93 | 1,463.18 | 1,715.24 | 2,138.50 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
103.89% | 117.87% | 150.15% | 220.23% | |
Selling, General and Administrative Expense of Revenue |
69.04% | 81.15% | 104.25% | 150.10% | |
Share Based Compensation of Revenue |
19.60% | 22.64% | 27.56% | 43.52% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.00 | 1.14 | 1.13 | 1.00 | |
Depreciation/Fixed assets |
(23.94) | (44.77) | (58.12) | (92.98) | |
Capex/Depreciation |
0.04 | 0.00 | 0.00 | 13.83 | |
Revenue per Share |
2.83 | 2.46 | 1.99 | 1.29 | |
Operating CF per Share |
(2.48) | (3.15) | (3.73) | (3.59) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (1.90) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 1.48 | |
Net Profit Margin |
(87.60%) | (112.01%) | (165.60%) | (279.31%) |
Columns are period end dates